Alkem Medtech, a subsidiary of Alkem Medtech, has signed a binding offer to acquire a 100% stake in orthopedic implant maker Bombay Ortho Industries, a 100% stake of Rs 147 trillion. Bombay Ortho has expertise within the hip and knee implant segments and is growing rapidly.
Alkem said it intends to close the acquisition of Adroit by April 1, 2025, and that by June 30, 2025, Bombay Ortho will be subject to customary closure conditions.
“Alkem is now able to diversify its portfolio, strengthen its market penetration and strengthen its presence in the dermatology and cosmetic growth segment,” said Alkem Chairman Bn Singh.
“MedTech is a fast-growing space in India, with high patient needs for quality products. We aim to meet the growing demand for implants in India through acquisitions in the medical device segment. Last August, Alkem joined forces with US-based Exactech to manufacture and sell large-scale joint implants in India. With this collaboration, Alkem MedTech will provide access to marketing rights for Exactech brands such as Truliant, Optetrak, Logic Fit, Alteon, Acumatch, Novation, Novation CFS. December 31, 2024.
Alkem on Friday recorded a 5.2% net profit jump from the previous year, earning a net profit of 626 crore in Q3FY25, growing domestic formulation sales and cost management.
The company reported Rs 595 in the corresponding quarter of the previous year.
Revenue from operations increased 1.5% to Rs 3,374.3 years from Q3FY25.
Earnings before interest, tax, depreciation and amortization (EBITDA) increased to 759.4 crores from the previous year, resulting in an EBITDA margin of 22.5% compared to 21.3% on Q3FY24.
Quarterly R&D expenses were Rs 131.2 or 3.9% of total revenue.
Domestic formulation sales, which contributed to 71.1% of revenue, rose 5.9% from the previous year to Rs 2,365.
According to data analytics firm IQVIA (SSA) data, Q3FY25 data recorded a year-over-year 6% against the Indian drug market (IPM). This was an increase of 7.2%. At Q3FY25, seven treatments outperformed the market: vitamins, antidiabetics, stomach intestines, neurological, guinec, guinec, respiratory and urology.
International sales were 960.5 rupees, down 6.2% year-on-year. The overall contribution of US sales to total sales was 19.1% in Q3FY25.
